肺大细胞神经内分泌癌N分期:[18F]FDG PET/CT与病理金标准的诊断价值比较
该单中心回顾性分析纳入46例肺大细胞神经内分泌癌(LCNEC)患者,术前均行[18F]FDG PET/CT,以术后或纵隔镜病理N分期为参考标准。PET/CT诊断淋巴结转移的灵敏度93%、特异度87%、准确率89%、PPV 78%、NPV 96%,评分者间一致性高(κ=0.82)。
要点
- PET/CT对LCNEC淋巴结转移诊断灵敏度93%、特异度87%、NPV 96%。
- cN0者可考虑省略术前有创纵隔分期,cN1-cN3需组织学确认。
- 淋巴结FDG摄取较原发灶低33%-67%的假阳性病例需警惕。
核心结论
- [18F]FDG PET/CT在LCNEC的N分期中兼具高灵敏度和特异度,NPV优秀但PPV略低。
- PET/CT诊断为cN0时可省略术前有创纵隔分期,cN1-cN3阶段需组织学确认。
研究设计与样本
- 单中心回顾性分析纳入2014年3月至2020年12月46例LCNEC患者,术前均行[18F]FDG PET/CT。
- 38例接受手术、8例接受纵隔镜,以最终病理N分期(pN0-pN3)为参考标准计算诊断效能。
主要发现
- 每例患者切除并组织学处理14±7枚淋巴结(范围4-32枚)。
- 31/46例无淋巴结转移,8/46例为pN1,5/46例为pN2,2/46例为pN3。
- [18F]FDG PET/CT诊断淋巴结转移灵敏度93%、特异度87%、准确率89%、PPV 78%、NPV 96%。
- 4例假阳性病例中淋巴结FDG摄取较对应LCNEC原发灶低33%至67%。
- 评分者间一致性高,κ=0.82。
关键数值与推荐
- PET/CT cN0者可省略术前有创纵隔分期。
- PET/CT cN1-cN3者需组织学确认,尤其淋巴结FDG摄取较原发灶仅中度增高时。
临床怎么用
- LCNEC术前分期可优先采用[18F]FDG PET/CT评估淋巴结状态。
- PET/CT判为cN0时可考虑免去有创纵隔分期,cN1-cN3则应行病理确认。
- 判读时注意淋巴结FDG摄取相对原发灶的比值,摄取仅中度增高者需警惕假阳性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Large cell neuroendocrine carcinoma of the lung (LCNEC) is a rare entity occurring in less than 4% of all lung cancers. Due to its low differentiation and high glucose transporter 1 (GLUT1) expression, LCNEC demonstrates an increased glucose turnover. Thus, PET/CT with 2-[18F]-fluoro-deoxyglucose ([18F]FDG) is suitable for LCNEC staging. Surgery with curative intent is the treatment of choice in early stage LCNEC. Prerequisite for this is correct lymph node staging. This study aimed at evaluating the diagnostic performance of [18F]FDG PET/CT validated by histopathology following surgical resection or mediastinoscopy. N-staging interrater-reliability was assessed to test for robustness of the [18F]FDG PET/CT findings. METHODS: Between 03/2014 and 12/2020, 46 patients with LCNEC were included in this single center retrospective analysis. All underwent [18F]FDG PET/CT for pre-operative staging and subsequently either surgery (n = 38) or mediastinoscopy (n = 8). Regarding the lymph node involvement, sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) were calculated for [18F]FDG PET/CT using the final histopathological N-staging (pN0 to pN3) as reference. RESULTS: Per patient 14 ± 7 (range 4-32) lymph nodes were resected and histologically processed. 31/46 patients had no LCNEC spread into the lymph nodes. In 8/46 patients, the final stage was pN1, in 5/46 pN2 and in 2/46 pN3. [18F]FDG PET/CT diagnosed lymph node metastasis of LCNEC with a sensitivity of 93%, a specificity of 87%, an accuracy of 89%, a PPV of 78% and a NPV of 96%. In the four false positive cases, the [18F]FDG uptake of the lymph nodes was 33 to 67% less in comparison with that of the respective LCNEC primary. Interrater-reliability was high with a strong level of agreement (κ = 0.82). CONCLUSIONS: In LCNEC N-staging with [18F]FDG PET/CT demonstrates both high sensitivity and specificity, an excellent NPV but a slightly reduced PPV. Accordingly, preoperative invasive mediastinal staging may be omitted in cases with cN0 disease by [18F]FDG PET/CT. In [18F]FDG PET/CT cN1-cN3 stages histological confirmation is warranted, particularly in case of only moderate [18F]FDG uptake as compared to the LCNEC primary.
引用
- Hautzel H, Alnajdawi Y, Fendler WP, et al. N-staging in large cell neuroendocrine carcinoma of the lung: diagnostic value of [18F]FDG PET/CT compared to the histopathology reference standard. EJNMMI Res. 2021. PMID: 34292419. doi:10.1186/s13550-021-00811-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。